Scholarlink

<p>To evaluate the tear levels of Lymphotoxin-alpha (LT-α) and the clinical efficacy of intense pulsed light (IPL) treatment in patients with dry eye disease (DED). This randomized study included 28 participants with DED who received 3 IPL therapies at Week 0 (Baseline), Week 3(3W), and Week 6(6W) (<i>N</i> = 30 eyes), or 2 IPL therapies at Baseline,&#xa0;3W and a sham IPL therapy at 6W (<i>N</i> = 26 eyes). All participants were examined at Baseline, 3W, 6W, Week 9(9W), and Week 12(12W) for non-invasive break-up time (NITBUT), LT-α, meibomian gland quality (MGQ), tear meniscus height (TMH), conjunctivocorneal staining score (CFS), meibomian gland expression (MGEx), tear-film lipid layer (TFLL), and ocular surface disease index (OSDI). Baseline measures exhibited no significant differences between the groups (<i>all p &gt; 0.05</i>). At&#xa0;6W, NITBUT, MGEx, CFS, and OSDI were significantly improved compared with the Baseline (<i>p</i> &lt; <i>0.05</i>). At 12W, a comparison between the 3 IPL therapy group and 2 IPL therapy group found significant improvements in the NITBUT (<i>p = 0.002</i>), TMH (<i>p</i> = 0.011), TFLL (<i>p</i> = <i>0.009</i>), MGEx (<i>p = 0.011</i>), MGQ (<i>p = 0.021</i>), LT-α (<i>p = 0.034</i>), while the CFS (<i>p</i> = <i>0.104</i>), OSDI (<i>p</i> = <i>0.189</i>) had no significant improvements. IPL treatment can improve the clinical symptoms and signs of DED. The potential long-term benefit of 3 IPL treatments is better than 2 treatments.</p><p><b>Trial registration</b>: ClinicalTrials.gov, TRN: NCT0626923, Registration date: 21 February 2024.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Intense pulsed light treatment improved tear film quality and reduced ocular surface inflammation in dry eye patients

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月21日

查看全文
  • Jiayan Chen,
  • Ying Zhang,
  • Sile Yu,
  • Qiuyue Zhang,
  • Xinyue Liu,
  • Yang Xia,
  • Wei He,
  • Guanghao Qin,
  • Xingru He

摘要

To evaluate the tear levels of Lymphotoxin-alpha (LT-α) and the clinical efficacy of intense pulsed light (IPL) treatment in patients with dry eye disease (DED). This randomized study included 28 participants with DED who received 3 IPL therapies at Week 0 (Baseline), Week 3(3W), and Week 6(6W) (N = 30 eyes), or 2 IPL therapies at Baseline, 3W and a sham IPL therapy at 6W (N = 26 eyes). All participants were examined at Baseline, 3W, 6W, Week 9(9W), and Week 12(12W) for non-invasive break-up time (NITBUT), LT-α, meibomian gland quality (MGQ), tear meniscus height (TMH), conjunctivocorneal staining score (CFS), meibomian gland expression (MGEx), tear-film lipid layer (TFLL), and ocular surface disease index (OSDI). Baseline measures exhibited no significant differences between the groups (all p > 0.05). At 6W, NITBUT, MGEx, CFS, and OSDI were significantly improved compared with the Baseline (p < 0.05). At 12W, a comparison between the 3 IPL therapy group and 2 IPL therapy group found significant improvements in the NITBUT (p = 0.002), TMH (p = 0.011), TFLL (p = 0.009), MGEx (p = 0.011), MGQ (p = 0.021), LT-α (p = 0.034), while the CFS (p = 0.104), OSDI (p = 0.189) had no significant improvements. IPL treatment can improve the clinical symptoms and signs of DED. The potential long-term benefit of 3 IPL treatments is better than 2 treatments.

Trial registration: ClinicalTrials.gov, TRN: NCT0626923, Registration date: 21 February 2024.